Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Events & presentations

07 Jul 2021

French Retail Investors Webcast on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®

29 Jun 2021 - 01 Jul 2021

Biotech Outsourcing Strategies (BOS) 2021, Virtual

24 Jun 2021 - 25 Jun 2021

UMDF Mitochondrial Medicine 2021 – virtual

15 Jun 2021

Clinical Operations Strategy Meeting online 2021

14 Jun 2021 - 18 Jun 2021

BIO US 2021 – Digital

04 Jun 2021

KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

19 May 2021 - 21 May 2021

Advanced Therapies – Virtual

01 May 2021 - 07 May 2021

2021 ARVO Annual Meeting, virtual

29 Apr 2021

Annual General Meeting 2021

27 Apr 2021 - 29 Apr 2021

Mitochondria-Targeted Drug Development Summit, Digital

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 17
  • View next 9 articles
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page